Figure 1 (IMAGE)

Impact Journals LLC

Figure 1

Caption

Monitoring of the EGFR sensitizing (blue curves) and T790M (red curves) mutations in plasma during the first month of treatment with osimertinib in non-small cell lung cancer patients. Representative cases of good and poor responders are shown. Numbers indicate clearing times for the EGFR sensitizing mutation (blue) or the T790M mutation (red). NR, clearing not reached.

Credit

Correspondence to - Antonio Marchetti - amarchetti@unich.it

Usage Restrictions

CCBY

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.